Found: 4
Select item for more details and to access through your institution.
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
- Published in:
- Patient Preference & Adherence, 2016, v. 10, p. 1945, doi. 10.2147/PPA.S114619
- By:
- Publication type:
- Article
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
- Published in:
- BMC Neurology, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2377-13-82
- By:
- Publication type:
- Article
Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
- Published in:
- European Neurology, 2016, v. 76, n. 1/2, p. 40, doi. 10.1159/000447630
- By:
- Publication type:
- Article